Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Monoclonal Antibodies (MAs) Market Expected To Grow In Terms Of Size?

In the past few years, there has been a significant increase in the market size of monoclonal antibodies (MAbs). The market is projected to expand from $231.42 billion in 2024 to $256.03 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.6%. The preceding growth can be attributed to several factors such as the increasing prevalence of chronic ailments, growing investments in R&D, enhanced mabs awareness and an expanding aging population.

Expect a swift expansion in the market size of monoclonal antibodies (MAbs) in the forthcoming years. The market is set to rise to “$413.13 billion in 2029”, witnessing a compound annual growth rate (CAGR) of 12.7%. Factors contributing to this growth span across a wide range, including increasing therapeutic indications, personalized medicine, biosimilars and generics, combination therapies, readiness for pandemics, and biopharmaceutical investments. Key trends shaping the forecast period include advancements in immunotherapy, the adoption of subcutaneous administration, the emergence of next-generation antibodies, new subcutaneous formulations, incorporation of digital health, and advancements in biotechnology.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2554&type=smp

What Drivers Are Accelerating Expansion Of The Monoclonal Antibodies (MAs) Market?

The rising utilization of cost-effective biosimilar monoclonal antibodies is propelling the growth of the monoclonal antibody market. The objective of biosimilars is to manage the escalating healthcare costs and deal with the economic strain from patient pods and governments, in an effort to decrease medication expenses and broaden the reach of treatment. Biosimilars are drugs that are designed to mirror the properties of an already sanctioned biological drug. A biosimilar monoclonal antibody is 20%-25% cheaper than the original biologic drug. The count of clinical tests for a biosimilar is pretty less compared to the original biologic drug, which accounts for the reason behind their low pricing. In India, an updated biosimilar policy named ‘Guidelines on Similar Biologics’ devised by the Central Drugs Standard Control Organization (CSDCO) is anticipated to provide a significant impetus to the Indian biosimilar drugs industry.

How Is The Monoclonal Antibodies (MAs) Market Categorized Across Applications And Types?

The monoclonal antibodies (mas) market covered in this report is segmented –

1) By Source: Murine, Chimeric, Humanized, Human

2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications

3) By End Users: Hospitals, Private Clinics, Research Institute

Subsegments:

1) By Murine: Fully Murine MAbs, Murine-Derived MAbs

2) By Chimeric: Chimeric MAbs With Murine Variable Regions, Chimeric MAbs With Human Constant Regions

3) By Humanized: Humanized MAbs With Minor Murine Components, Fully Humanized MAbs

4) By Human: Fully Human MAbs, Engineered Human MAbs

How Are Market Trends Influencing Competition In The Monoclonal Antibodies (MAs) Market?

In recent times, the monoclonal antibody market has experienced numerous strategic endeavors. Major players in this market are tactically acquiring startups and companies of medium size to increase their range of products and services. Strategic alliances, acquisitions, and partnership agreements permit vendors to increase their current product offerings and geographical reach. For example, Sanofi S.A., a pharmaceutical and healthcare company based in France, announced a strategic alliance with Seagen Inc, a US-based pharmaceutical enterprise specializing in developing innovative, effective monoclonal antibody-based cancer treatments in March 2022. This collaboration will utilize both Seagen’s and Sanofi’s exclusive monoclonal antibody (mAb) and antibody-drug conjugate (ADC) technologies to design, develop, and market ADCs for up to three cancer targets. Moreover, Boehringer Ingelheim, a German research-driven pharmaceutical organization, reported a partnership with MabGenesis, Inc., a Japanese biopharmaceutical firm leading the development of therapeutic monoclonal antibody drugs. This collaboration led to the discovery and development of novel therapeutic monoclonal antibodies for treating various diseases and strategic research and development strategies. Firms within the industry are progressively rearranging their portfolios chasing beneficial inorganic growth opportunities. Additionally, the M&A interest is being driven by robust company balance sheets, liquid debt markets, and continued favorable interest rates worldwide.

Who Are The Primary Market Leaders In The Monoclonal Antibodies (MAs) Market?

Major companies operating in the monoclonal antibodies (MAbs) market include Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Novartis International AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Inc., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Biopharma Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals plc, Jiangsu Hengrui Medicine Co. Ltd., Piramal Enterprises Ltd., Troikaa Pharmaceuticals Ltd., CD BioSciences Inc., Kanto Corporation, Molecular Depot LLC, Epigentek Group Inc., Creative Biolabs Inc., Advanced ChemTech Inc., Diagnostic BioSystems Inc., Tonbo Biosciences Inc., Abraxis LLC, GlaxoSmithKline plc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

What Are The Emerging Regional Trends Driving The Monoclonal Antibodies (MAs) Market?

North America was the largest region in the monoclonal antibodies (MAbS) market in 2024. The regions covered in the monoclonal antibodies (MABS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=2554&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model